S&P 500   3,851.90 (+0.59%)
DOW   31,235.29 (-0.53%)
QQQ   316.75 (+1.25%)
AAPL   123.75 (+2.28%)
MSFT   233.96 (+2.17%)
FB   263.40 (+3.42%)
GOOGL   2,031.88 (+0.79%)
AMZN   3,094.72 (+1.23%)
TSLA   677.50 (-0.69%)
NVDA   551.51 (+3.61%)
BABA   241.17 (+0.41%)
CGC   32.66 (-1.66%)
GE   12.74 (-0.16%)
MU   91.90 (+4.29%)
NIO   46.66 (-0.32%)
AMD   84.71 (+2.78%)
T   28.24 (-1.36%)
F   11.83 (+0.60%)
ACB   10.77 (-0.46%)
DIS   189.71 (-0.66%)
BA   213.80 (-1.22%)
NFLX   548.10 (+0.26%)
BAC   35.16 (-2.14%)
S&P 500   3,851.90 (+0.59%)
DOW   31,235.29 (-0.53%)
QQQ   316.75 (+1.25%)
AAPL   123.75 (+2.28%)
MSFT   233.96 (+2.17%)
FB   263.40 (+3.42%)
GOOGL   2,031.88 (+0.79%)
AMZN   3,094.72 (+1.23%)
TSLA   677.50 (-0.69%)
NVDA   551.51 (+3.61%)
BABA   241.17 (+0.41%)
CGC   32.66 (-1.66%)
GE   12.74 (-0.16%)
MU   91.90 (+4.29%)
NIO   46.66 (-0.32%)
AMD   84.71 (+2.78%)
T   28.24 (-1.36%)
F   11.83 (+0.60%)
ACB   10.77 (-0.46%)
DIS   189.71 (-0.66%)
BA   213.80 (-1.22%)
NFLX   548.10 (+0.26%)
BAC   35.16 (-2.14%)
S&P 500   3,851.90 (+0.59%)
DOW   31,235.29 (-0.53%)
QQQ   316.75 (+1.25%)
AAPL   123.75 (+2.28%)
MSFT   233.96 (+2.17%)
FB   263.40 (+3.42%)
GOOGL   2,031.88 (+0.79%)
AMZN   3,094.72 (+1.23%)
TSLA   677.50 (-0.69%)
NVDA   551.51 (+3.61%)
BABA   241.17 (+0.41%)
CGC   32.66 (-1.66%)
GE   12.74 (-0.16%)
MU   91.90 (+4.29%)
NIO   46.66 (-0.32%)
AMD   84.71 (+2.78%)
T   28.24 (-1.36%)
F   11.83 (+0.60%)
ACB   10.77 (-0.46%)
DIS   189.71 (-0.66%)
BA   213.80 (-1.22%)
NFLX   548.10 (+0.26%)
BAC   35.16 (-2.14%)
S&P 500   3,851.90 (+0.59%)
DOW   31,235.29 (-0.53%)
QQQ   316.75 (+1.25%)
AAPL   123.75 (+2.28%)
MSFT   233.96 (+2.17%)
FB   263.40 (+3.42%)
GOOGL   2,031.88 (+0.79%)
AMZN   3,094.72 (+1.23%)
TSLA   677.50 (-0.69%)
NVDA   551.51 (+3.61%)
BABA   241.17 (+0.41%)
CGC   32.66 (-1.66%)
GE   12.74 (-0.16%)
MU   91.90 (+4.29%)
NIO   46.66 (-0.32%)
AMD   84.71 (+2.78%)
T   28.24 (-1.36%)
F   11.83 (+0.60%)
ACB   10.77 (-0.46%)
DIS   189.71 (-0.66%)
BA   213.80 (-1.22%)
NFLX   548.10 (+0.26%)
BAC   35.16 (-2.14%)
Log in
NASDAQ:BIIB

Biogen Competitors

$272.84
-4.42 (-1.59 %)
(As of 02/26/2021 01:15 PM ET)
Add
Compare
Today's Range
$269.64
Now: $272.84
$278.96
50-Day Range
$250.44
MA: $272.22
$284.63
52-Week Range
$223.25
Now: $272.84
$363.92
Volume26,983 shs
Average Volume1.33 million shs
Market Capitalization$41.56 billion
P/E Ratio9.03
Dividend YieldN/A
Beta0.53

Competitors

Biogen (NASDAQ:BIIB) Vs. AMGN, GILD, VRTX, REGN, ALXN, and SGEN

Should you be buying BIIB stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Biogen, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), and Seagen (SGEN).

Amgen (NASDAQ:AMGN) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Valuation & Earnings

This table compares Amgen and Biogen's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$23.36 billion5.57$7.84 billion$14.8215.19
Biogen$14.38 billion2.89$5.89 billion$33.578.12

Amgen has higher revenue and earnings than Biogen. Biogen is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Amgen and Biogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amgen29.42%95.55%15.52%
Biogen35.63%51.00%23.54%

Analyst Ratings

This is a summary of current recommendations for Amgen and Biogen, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amgen0111402.56
Biogen5151202.22

Amgen currently has a consensus target price of $256.0909, suggesting a potential upside of 13.76%. Biogen has a consensus target price of $304.4667, suggesting a potential upside of 11.51%. Given Amgen's stronger consensus rating and higher possible upside, research analysts plainly believe Amgen is more favorable than Biogen.

Volatility and Risk

Amgen has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500.

Institutional & Insider Ownership

75.2% of Amgen shares are owned by institutional investors. Comparatively, 83.5% of Biogen shares are owned by institutional investors. 0.4% of Amgen shares are owned by company insiders. Comparatively, 0.5% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Amgen beats Biogen on 9 of the 14 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Valuation & Earnings

This table compares Gilead Sciences and Biogen's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gilead Sciences$22.45 billion3.46$5.39 billion$6.1410.09
Biogen$14.38 billion2.89$5.89 billion$33.578.12

Biogen has lower revenue, but higher earnings than Gilead Sciences. Biogen is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

76.4% of Gilead Sciences shares are owned by institutional investors. Comparatively, 83.5% of Biogen shares are owned by institutional investors. 0.1% of Gilead Sciences shares are owned by company insiders. Comparatively, 0.5% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Gilead Sciences and Biogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gilead Sciences5.48%37.77%12.76%
Biogen35.63%51.00%23.54%

Volatility and Risk

Gilead Sciences has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for Gilead Sciences and Biogen, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gilead Sciences2121202.38
Biogen5151202.22

Gilead Sciences currently has a consensus target price of $96.0370, suggesting a potential upside of 55.05%. Biogen has a consensus target price of $304.4667, suggesting a potential upside of 11.51%. Given Gilead Sciences' stronger consensus rating and higher possible upside, research analysts plainly believe Gilead Sciences is more favorable than Biogen.

Summary

Biogen beats Gilead Sciences on 8 of the 13 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

Earnings and Valuation

This table compares Vertex Pharmaceuticals and Biogen's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vertex Pharmaceuticals$4.16 billion13.22$1.18 billion$4.2949.35
Biogen$14.38 billion2.89$5.89 billion$33.578.12

Biogen has higher revenue and earnings than Vertex Pharmaceuticals. Biogen is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

92.2% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 83.5% of Biogen shares are held by institutional investors. 0.7% of Vertex Pharmaceuticals shares are held by company insiders. Comparatively, 0.5% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Vertex Pharmaceuticals and Biogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vertex Pharmaceuticals38.51%28.55%20.68%
Biogen35.63%51.00%23.54%

Volatility and Risk

Vertex Pharmaceuticals has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Vertex Pharmaceuticals and Biogen, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vertex Pharmaceuticals042312.89
Biogen5151202.22

Vertex Pharmaceuticals presently has a consensus target price of $291.8462, suggesting a potential upside of 37.98%. Biogen has a consensus target price of $304.4667, suggesting a potential upside of 11.51%. Given Vertex Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Vertex Pharmaceuticals is more favorable than Biogen.

Summary

Vertex Pharmaceuticals beats Biogen on 10 of the 15 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

Earnings and Valuation

This table compares Regeneron Pharmaceuticals and Biogen's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regeneron Pharmaceuticals$7.86 billion6.20$2.12 billion$21.4721.20
Biogen$14.38 billion2.89$5.89 billion$33.578.12

Biogen has higher revenue and earnings than Regeneron Pharmaceuticals. Biogen is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 83.5% of Biogen shares are held by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are held by company insiders. Comparatively, 0.5% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Regeneron Pharmaceuticals and Biogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Regeneron Pharmaceuticals38.28%28.97%20.11%
Biogen35.63%51.00%23.54%

Volatility and Risk

Regeneron Pharmaceuticals has a beta of 0.3, meaning that its share price is 70% less volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Regeneron Pharmaceuticals and Biogen, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Regeneron Pharmaceuticals061712.79
Biogen5151202.22

Regeneron Pharmaceuticals presently has a consensus target price of $621.1481, suggesting a potential upside of 37.80%. Biogen has a consensus target price of $304.4667, suggesting a potential upside of 11.51%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than Biogen.

Summary

Regeneron Pharmaceuticals beats Biogen on 9 of the 15 factors compared between the two stocks.

Alexion Pharmaceuticals (NASDAQ:ALXN) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

Earnings and Valuation

This table compares Alexion Pharmaceuticals and Biogen's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alexion Pharmaceuticals$4.99 billion6.74$2.40 billion$9.7415.71
Biogen$14.38 billion2.89$5.89 billion$33.578.12

Biogen has higher revenue and earnings than Alexion Pharmaceuticals. Biogen is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

87.3% of Alexion Pharmaceuticals shares are held by institutional investors. Comparatively, 83.5% of Biogen shares are held by institutional investors. 4.0% of Alexion Pharmaceuticals shares are held by company insiders. Comparatively, 0.5% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Alexion Pharmaceuticals and Biogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alexion Pharmaceuticals16.32%23.16%14.76%
Biogen35.63%51.00%23.54%

Volatility and Risk

Alexion Pharmaceuticals has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Alexion Pharmaceuticals and Biogen, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alexion Pharmaceuticals017712.36
Biogen5151202.22

Alexion Pharmaceuticals presently has a consensus target price of $153.1250, suggesting a potential upside of 0.42%. Biogen has a consensus target price of $304.4667, suggesting a potential upside of 11.51%. Given Biogen's higher possible upside, analysts plainly believe Biogen is more favorable than Alexion Pharmaceuticals.

Summary

Biogen beats Alexion Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Seagen (NASDAQ:SGEN) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

Profitability

This table compares Seagen and Biogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Seagen25.34%20.46%16.67%
Biogen35.63%51.00%23.54%

Institutional and Insider Ownership

87.2% of Seagen shares are held by institutional investors. Comparatively, 83.5% of Biogen shares are held by institutional investors. 31.1% of Seagen shares are held by company insiders. Comparatively, 0.5% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Seagen and Biogen, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Seagen151112.67
Biogen5151202.22

Seagen presently has a consensus target price of $188.4615, suggesting a potential upside of 24.89%. Biogen has a consensus target price of $304.4667, suggesting a potential upside of 11.51%. Given Seagen's stronger consensus rating and higher possible upside, analysts plainly believe Seagen is more favorable than Biogen.

Volatility and Risk

Seagen has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500.

Earnings and Valuation

This table compares Seagen and Biogen's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Seagen$916.71 million29.87$-158,650,000.00($1.33)-113.65
Biogen$14.38 billion2.89$5.89 billion$33.578.12

Biogen has higher revenue and earnings than Seagen. Seagen is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Summary

Seagen beats Biogen on 8 of the 15 factors compared between the two stocks.

Ad Dear Wallstreet
This may be 2021's Hottest Ground Floor Story
This oil company is creating trust in the massive trillion dollar trading world

Biogen Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.5$225.14-1.1%$131.41 billion$23.36 billion18.16
Gilead Sciences logo
GILD
Gilead Sciences
2.7$61.97-1.3%$78.71 billion$22.45 billion63.89
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.4$211.71-0.6%$55.37 billion$4.16 billion26.73Analyst Upgrade
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$455.06-0.4%$48.55 billion$7.86 billion16.63Analyst Report
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.9$153.00-0.4%$33.78 billion$4.99 billion35.75
Seagen logo
SGEN
Seagen
1.7$151.15-0.7%$27.19 billion$916.71 million59.51
Exact Sciences logo
EXAS
Exact Sciences
1.6$133.57-1.7%$22.20 billion$876.29 million-60.44Analyst Downgrade
Insider Selling
News Coverage
Incyte logo
INCY
Incyte
1.9$79.14-0.9%$17.25 billion$2.16 billion-50.41Insider Buying
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$147.83-0.8%$17.15 billion$219.75 million-18.88
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.9$77.02-6.2%$14.84 billion$1.70 billion17.62Earnings Announcement
Insider Selling
Gap Up
Novavax logo
NVAX
Novavax
1.2$229.37-3.4%$14.10 billion$18.66 million-43.94Upcoming Earnings
Repligen logo
RGEN
Repligen
1.5$213.31-2.9%$10.90 billion$270.24 million260.13Earnings Announcement
Analyst Report
Analyst Revision
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.1$109.32-2.3%$10.03 billion$788.10 million117.55Analyst Revision
United Therapeutics logo
UTHR
United Therapeutics
1.7$168.87-0.0%$7.50 billion$1.45 billion15.98Earnings Announcement
Analyst Report
News Coverage
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.2$52.81-1.1%$7.47 billion$1.12 billion110.02Earnings Announcement
Analyst Downgrade
Analyst Revision
News Coverage
Exelixis logo
EXEL
Exelixis
1.9$21.89-0.3%$6.85 billion$967.78 million45.61Insider Selling
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$47.40-0.2%$6.40 billion$195.99 million296.25Earnings Announcement
Analyst Revision
News Coverage
Emergent BioSolutions logo
EBS
Emergent BioSolutions
1.8$96.67-0.5%$5.18 billion$1.11 billion31.08Analyst Upgrade
Analyst Revision
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.3$80.26-1.0%$4.62 billion$806.43 million-11.37Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
ChemoCentryx logo
CCXI
ChemoCentryx
1.4$68.49-3.8%$4.56 billion$36.13 million-102.22Upcoming Earnings
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$12.15-1.9%$3.11 billion$182.24 million-10.57Upcoming Earnings
Alkermes logo
ALKS
Alkermes
1.2$18.81-3.3%$3.10 billion$1.17 billion-40.89
OPKO Health logo
OPK
OPKO Health
1.9$4.55-2.9%$2.96 billion$901.90 million-25.28Gap Down
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$150.85-0.4%$2.42 billion$120.28 million-152.37
Myriad Genetics logo
MYGN
Myriad Genetics
1.0$30.68-1.5%$2.27 billion$638.60 million-11.80Earnings Announcement
Analyst Report
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$122.08-0.8%$1.90 billionN/A-11.03Earnings Announcement
Analyst Report
News Coverage
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.1$10.83-3.3%$1.85 billion$48.83 million-14.25Earnings Announcement
Analyst Report
News Coverage
Gap Down
ImmunoGen logo
IMGN
ImmunoGen
1.3$8.85-0.8%$1.71 billion$82.27 million-21.59
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.64-3.9%$1.58 billion$102.43 million-19.40Earnings Announcement
Analyst Revision
News Coverage
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.5$9.23-2.1%$1.45 billion$428.41 million13.38Analyst Report
MannKind logo
MNKD
MannKind
1.0$5.74-2.3%$1.30 billion$63.04 million-27.33Analyst Report
Analyst Revision
Codexis logo
CDXS
Codexis
1.1$21.96-3.3%$1.26 billion$68.46 million-62.74Earnings Announcement
Analyst Report
Gap Down
Innoviva logo
INVA
Innoviva
1.4$11.56-0.5%$1.18 billion$261.02 million5.90
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.8$27.89-1.4%$1.09 billion$3.57 million-12.51Analyst Report
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$18.64-3.8%$1.06 billion$227.19 million51.78
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.1$5.35-13.1%$996.45 million$150,000.00-7.64Earnings Announcement
Gap Down
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.8$7.53-0.7%$906.46 million$322.07 million-7.17Gap Up
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$9.28-12.1%$899.01 million$35.22 million-6.77Earnings Announcement
News Coverage
Gap Down
Agenus logo
AGEN
Agenus
1.6$4.08-0.2%$777.71 million$150.05 million-3.74
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
1.9$22.41-2.9%$760.30 million$252 million-2.29Earnings Announcement
Analyst Downgrade
News Coverage
Gap Down
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$4.24-2.4%$699.58 million$59.29 million-28.26Upcoming Earnings
Analyst Report
Gap Down
Curis logo
CRIS
Curis
1.3$9.65-1.0%$573.47 million$10 million-11.77
Geron logo
GERN
Geron
1.4$1.79-1.4%$561.95 million$460,000.00-5.10
Molecular Templates logo
MTEM
Molecular Templates
2.0$11.06-0.4%$550.60 million$22.27 million-5.42Analyst Upgrade
Insider Buying
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.52-2.3%$525.32 million$109.33 million-2.59
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$6.03-1.5%$524.62 million$143.01 million-1.15Earnings Announcement
Analyst Report
Analyst Revision
Verastem logo
VSTM
Verastem
1.8$2.45-3.7%$400.67 million$17.46 million-1.74Analyst Upgrade
XOMA logo
XOMA
XOMA
1.8$36.52-0.9%$399.00 million$18.37 million-32.90Gap Up
Fortress Biotech logo
FBIO
Fortress Biotech
1.3$3.76-1.3%$347.64 million$36.63 million-4.42Analyst Report
News Coverage
PDL BioPharma logo
PDLI
PDL BioPharma
1.1$2.47-0.0%$282.14 million$54.76 million-2.19
This page was last updated on 2/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.